• Home

  • HEALTH CARE

  • HEALTHY LIFESTYLE

  • HYGIENE

  • COSMETICS

  • FOR HIM

  • PREGNANCY AND MOTHERHOOD

  • CHILD

    2. HEALTH CARE
    3. Clovate ointment 0.5mg/g 25g — Made in Poland — Free Delivery

    Clovate ointment 0.5mg/g 25g — Made in Poland — Free Delivery


    Brand: Jelfa
    Product Code: Clovate
    Availability: In Stock
    $20.72
    Add to Cart

    Indications

    Psoriasis (with the exception of common plaque psoriasis), resistant eczema, lichen planus, discoid lupus erythematosus and other skin diseases that cannot be treated with less active corticosteroids.

    Application

    The cream is especially effective for the treatment of wet or weeping skin surfaces. the ointment is suitable for the treatment of dry skin surfaces, as well as skin with lichen or scaly lesions. cream / ointment is applied in a thin layer to the affected areas of the skin 1-2 times a day until the condition improves. as with other highly active corticosteroids, treatment should be discontinued once disease control is achieved. improvement occurs individually, in patients who respond well to therapy, the result may appear in a few days. it is recommended to continue treatment for no more than 4 weeks; if there is no improvement in the condition, it is necessary to clarify or revise the diagnosis.
    To prevent exacerbation of the disease, repeated short courses of treatment with Cloveit can be carried out. If long-term permanent steroid therapy is needed, other, less potent preparations should be used. In very resistant lesions, especially in areas of hyperkeratosis, the anti-inflammatory effect of Cloveit can be enhanced if necessary by covering the affected area with plastic wrap. To achieve a positive result, an airtight bandage is applied all night. The effect already achieved is maintained by simply applying the preparation to the skin without covering it with a film.

    Contraindications

    Untreated skin infections. rosacea. common acne. itching without inflammation. perianal and genital itching. perioral dermatitis. hypersensitivity to the components of the preparation. dermatosis in children under the age of 1 year, including dermatitis.

    Side effects

    Infections and infestations: opportunistic infections.
    Immune system: local hypersensitivity.
    Endocrine system: hypothalamic-pituitary-adrenal system depression: Cushingoid features (eg, moon face, central obesity), delayed weight gain/height in children, osteoporosis, glaucoma, hyperglycemia/glucosuria, cataracts, hypertension, weight gain/obesity, decreased levels of endogenous cortisol, alopecia, brittle hair.
    Skin and subcutaneous tissues: pruritus, local burning sensation/pain in the skin, local skin atrophy*, atrophic streaks on the skin*, telangiectasias*, thinning of the skin*, wrinkling of the skin*, dry skin*, changes in pigmentation*, hypertrichosis, exacerbation of the main symptoms , allergic contact dermatitis/dermatitis, pustular psoriasis, erythema, rash, urticaria.
    General disorders and disorders at the site of application: irritation / pain at the site of application.
    *Skin disorders are secondary to local and/or systemic depression of the hypothalamic-pituitary-adrenal system.

    special instructions

    The preparation is used with caution in patients with a history of local hypersensitivity reactions to corticosteroids or any excipients. local hypersensitivity reactions (see side effects) may resemble symptoms of the disease being treated.
    The manifestation of hypercortisolism (Cushing's syndrome) and reverse suppression of the hypothalamic-pituitary-adrenal system with suppression of adrenal function in some individuals may be the result of increased systemic absorption of GCS. In the event of any of the above symptoms, the use of the preparation should be gradually discontinued by reducing the frequency of application or replacing with a less powerful corticosteroid. Sudden discontinuation of treatment may lead to glucocorticoid insufficiency (see SIDE EFFECTS). Risk factors for systemic effects are:
    - potency and composition of the topical steroid;
    - duration of application;
    - application to a large area of ​​​​the skin;
    - application on surfaces of contacting skin, for example, in areas of diaper rash or at the site of an occlusive dressing (in infants, diapers can play the role of an occlusive dressing);
    - increased hydration of the stratum corneum;
    - use on areas with thin skin, for example on the face; application to damaged skin or under other conditions where there is a violation of the skin barrier.
    Children. Compared with adults, children may absorb proportionally more topical corticosteroid and are therefore more susceptible to systemic side effects. This is due to the fact that children have an underdeveloped skin barrier and a larger skin surface relative to body weight compared to adults. Long-term use of corticosteroids in children aged 1–12 years should be avoided, if possible, as they are more likely to experience adrenal suppression.
    Children are more susceptible to the development of atrophic changes when using corticosteroids. If Clovate is needed for the treatment of children, it is recommended that it be continued for several days and reviewed weekly.
    Risk of infection when applying an occlusive dressing. The risk of bacterial infections is increased in the warm, humid environments that can occur under occlusive dressings, so the skin should be carefully cleaned before a new dressing is applied.
    Treatment of psoriasis. Topical corticosteroids should be used with caution in the treatment of psoriasis, as relapses, tolerance, the risk of generalization of pustular psoriasis, and the development of symptoms of local or systemic toxicity caused by impaired skin barrier function have been reported in some cases. In the case of use for the treatment of psoriasis, the patient should be under close medical supervision.
    associated infections. Each time the treatment of infected inflammatory skin lesions, it is necessary to prescribe appropriate antibacterial preparations. If infection spreads, topical corticosteroids should be discontinued and appropriate antibiotic treatment given.
    Chronic ulcers of the lower extremities. Sometimes topical corticosteroids are used to treat dermatitis that occurs around chronic leg ulcers. However, such use is associated with an increased incidence of local hypersensitivity reactions and the risk of local infections.
    Applying cream to the face. Applying a cream to the skin of the face is undesirable, since this area is more prone to atrophic changes. If necessary, use should be limited to a few days.
    Application on the eyelids. When applying the cream on the eyelids, avoid getting the preparation into the eyes, as repeated use can cause cataracts and glaucoma.
    Use during pregnancy and lactation. Pregnancy. There are limited data on the use of Cloveit in pregnant women.
    Topical application of corticosteroids in pregnant animals can cause intrauterine developmental disorders. Correspondence of these data concerning the person is not established. Cloveit should be prescribed during pregnancy only if the expected benefit to the mother outweighs the risk to the fetus. Apply the minimum amount of the preparation during the minimum period of treatment.
    Lactation. The safety of clobetasol propionate during lactation has not been established. It is not known whether the use of corticosteroids can lead to such systemic absorption, as a result of which a measurable amount of the preparation will be detected in breast milk. Cloveit should be used during breastfeeding only when the expected benefit to the mother outweighs the risk to the baby. When administered during breastfeeding, the cream should not be applied to the mammary glands in order to avoid accidental ingestion of the cream through the mouth to the child.
    Children. The preparation is contraindicated for the treatment of dermatoses, including dermatitis in children under the age of 1 year.
    The ability to influence the reaction rate when driving vehicles or working with other mechanisms. No studies have been conducted to investigate this effect. Given the profile of adverse reactions, the effect on the reaction rate when driving vehicles or working with other mechanisms is not expected.

    Interactions

    It has been shown that concomitant use with preparations that can inhibit sypza4 (for example, ritonavir, itraconazole) inhibits the metabolism of corticosteroids, which can cause a systemic effect. the extent to which such an interaction is clinically significant depends on the dose of the preparation, the route of administration of corticosteroids, and the potency of the cypza4 inhibitor.

    Overdose

    Symptoms. with normal use cloveit can be absorbed in quantities sufficient to cause a systemic effect. the likelihood of developing an acute overdose is very small, however, in the case of chronic overdose or improper use, signs of hypercortisolism may occur.
    Treatment. In case of an overdose, Cloveit should be gradually withdrawn by reducing the frequency of application of the cream or replacing it with a less powerful corticosteroid, taking into account the risk of corticosteroid insufficiency.
    Further treatment is carried out according to the clinical condition of the patient or according to national recommendations for the treatment of poisoning, if any.

    Storage conditions

    At a temperature not higher than 25 °C. do not freeze.

    There are no reviews for this product.
    VEV Healthcare Store © 2017